DALLAS - TelAve -- Thousands of patients prescribed Suboxone for opioid addiction treatment are now pursuing legal claims after experiencing severe dental deterioration, including tooth loss, infections, and multiple extractions. The U.S. Food and Drug Administration updated its safety labeling in 2022 to warn of serious dental problems associated with sublingual buprenorphine products — years after the drug entered the market.

Plaintiffs allege that Indivior, the manufacturer of Suboxone, failed to adequately warn patients and prescribers about the dental risks of dissolving the medication under the tongue, where prolonged acid exposure damages tooth enamel. Many patients report having no prior dental problems before starting Suboxone treatment.

More on TelAve News

• Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
• IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
• AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
• Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
• Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor

Legal experts note that individuals who took sublingual Suboxone, Subutex, or generic buprenorphine films and subsequently required dental surgery, extractions, or dentures may be eligible to file claims.

For current litigation updates and eligibility information, visit suboxoneinjury.com (http://suboxoneinjury.com/).